Although the three tiered approach had the considerable advantage of distinguishing PD-L1 negative disease (3tPD-L1-(0)), an important category in the decision tree guiding therapy in the current standard first line management of metastatic/recurrent HNSCC, the distribution of the patients in the resultant groups were dissimilar. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.